Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00423969 · ClinicalTrials.gov registry record · Phase 4
Galantamine Augmentation of Escitalopram for Treatment of Depression
A Phase 4 study, sponsored by Indiana University.
- Terminated
- Registry status
- Phase 4
- Development phase
- 20
- Enrollment target
NCT00423969 is a Phase 4 study that was terminated before completion, run by Indiana University. The registered enrollment target is 20 participants.
The verdict
NCT00423969, a Phase 4 study, was terminated before completion, sponsored by Indiana University.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 20 participants
- Enrollment target
Study Summary
The purpose of this study is to investigate whether the addition of galantamine to a commonly used antidepressant, escitalopram (Lexapro), will be useful in the treatment of memory and other thinking problems that are frequently seen in depression. At present, galantamine is approved for use in the treatment of Alzheimer's disease or dementia, but not for use for the treatment of depression in younger patients. Possible genetic effects of depressed individuals will also be studied. This study is involved in collecting blood from patients with depression. DNA, the genetic material in our cells, will be obtained from these blood samples. The DNA will be studied to determine the contribution of different genes to the development of depression. These blood samples are extremely useful to researchers who are trying to determine the genetic risk factors that may lead to depression.
Interventions
- DRUG Escitalopram
- DRUG Galantamine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2003-11 |
| Est. Completion | 2005-09 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00423969
The ClinicalTrials.gov registry entry for NCT00423969 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Indiana University, which has 890 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Escitalopram is the first listed.
NCT00423969 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00423969 about?
NCT00423969 is a clinical study titled "Galantamine Augmentation of Escitalopram for Treatment of Depression". The purpose of this study is to investigate whether the addition of galantamine to a commonly used antidepressant, escitalopram (Lexapro), will be useful in the treatment of memory and other thinking problems that are frequently seen in depression. At present, galantamine is approved for use in the ...
What is the current status of trial NCT00423969?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 20 participants. The study started on 2003-11. Estimated completion is 2005-09.
What interventions are being tested in trial NCT00423969?
The interventions under investigation include: Escitalopram (DRUG), Galantamine (DRUG).
Who is sponsoring clinical trial NCT00423969?
This trial is sponsored by Indiana University, which has 890 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.